InMed Pharmaceuticals (INM) Cash & Equivalents (2020 - 2026)

InMed Pharmaceuticals has reported Cash & Equivalents for 7 years, with the latest figure at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 10.64% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (up 10.64% YoY), and the FY2025 full-year result was $10.7 million, up 63.48% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.2 million, down from $7.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $11.5 million in Q4 2022, with the low at $4.7 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $7.6 million across 5 years, with a median of $6.7 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 41.45% — and 2025, when it surged 67.13%.
• InMed Pharmaceuticals' Cash & Equivalents stood at $11.5 million in 2022, then dropped by 16.74% to $9.5 million in 2023, then tumbled by 41.45% to $5.6 million in 2024, then rose by 25.38% to $7.0 million in 2025, then retreated by 25.71% to $5.2 million in 2026.
• The last three Cash & Equivalents figures came in at $5.2 million (Q1 2026), $7.0 million (Q4 2025), and $9.3 million (Q3 2025), per Business Quant data.